top of page
.png)
Journey of 2Sevnty Bio - Spin-off, Key Onco-deals, and Acquisition
🤝 Bristol Myers Squibb is set to acquire 2seventy bio in an all-cash transaction valued at approximately $286 million. After...
Oncofocus Team
Jun 20, 20251 min read
CGT Watch Newsletter: May'25 Edition
Welcome to the May edition of our CGT Watch newsletter! CARsgen’s satri-cel priority review & Ph2 results; Autolus’ obe-cel positive...
Oncofocus Team
Jun 20, 20259 min read
CGT Watch Newsletter: April'25 Edition
Welcome to the April edition of our CGT Watch newsletter! Autolus’ Aucatzyl’s UK approval; BrainChild Bio’s BCB-276 BTD; Lyell’s LYL314...
Oncofocus Team
Jun 20, 202511 min read
Onco-Summaries: Daily Oncology Updates at a Glance
12/06/2025 MAIA Biotechnology and Roche announce a master clinical supply agreement for hard-to-treat cancer therapies ( Ref ) MAIA...
Oncofocus Team
Jun 20, 20252 min read
FDA Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests
📢 The U.S. FDA launched a new program - the Commissioner’s National Priority Voucher (CNPV) - to shorten review timelines from 10-12...
Oncofocus Team
Jun 19, 20251 min read
Another billion dollar deal in the PD-(L)1xVEGF BsAb space
⭐ BioNTech SE and Bristol Myers Squibb entered into a global strategic partnership with a 50/50 profit/loss split to co-develop and...
Oncofocus Team
Jun 19, 20251 min read
bottom of page